What the reviews and appraisals show
The independent evidence reviews in this collection reach a consistent conclusion: the evidence that puberty blockers and cross-sex hormones improve gender distress, mental health or quality of life in minors is weak. The University of York reviews for England's Cass Review assessed 50 blocker studies and 53 hormone studies, each with only one rated high quality, and could draw no conclusions on blockers' effects on distress or mental health (Cass Review, 2024). An update of NICE's 2020 search found no new qualifying blocker study through 2023 (Zepf et al., 2024). The US government review, drawing on 17 earlier evidence reviews, rated evidence on mental health, quality of life and regret as very weak for every intervention (U.S. Department of Health and Human Services, 2025). A 2025 Utah review reached the opposite conclusion, but a critique argues it never graded overall certainty of evidence (Society for Evidence-Based Gender Medicine, 2026).
Appraisals of the guidelines themselves point the same way. Of 23 guidance documents rated with a standard appraisal instrument, only Sweden's and Finland's scored above 50% for rigor of development; WPATH's 2022 standards scored 35% and the Endocrine Society's 2017 guideline 42%, and most other guidance derived from those two (Taylor et al., 2024). A separate appraisal of six WPATH chapters scored rigor at 39–47% and applicability at 28–40%, with only two of eight raters recommending them unchanged (Zhang et al., 2026). The Endocrine Society graded the evidence behind every adolescent recommendation as low or very low yet issued some strong recommendations, and its commissioned reviews covered only bone and cardiometabolic safety (Hembree et al., 2017). WPATH stated that a systematic review of adolescent outcomes was "not possible" (Coleman et al., 2022).
Limits of the evidence
Much of this literature appraises process and reporting rather than whether specific advice is right, and low guideline scores do not by themselves show harm. Several critiques were funded or written by organizations that campaign on the issue, and critics of the Cass Review also have stakes. Policy-effect evidence is thin: a self-published analysis of US state bans found suicide-rate changes among all 15–19-year-olds close to zero, but with one to three years of data and an outcome diluted across a population in which affected youth are a very small share (Greene & Kingsbury, 2026).